Journal article
CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa
Molecular therapy, Vol.24(8), pp.1388-1394
08/2016
DOI: 10.1038/mt.2016.107
PMCID: PMC5023380
PMID: 27203441
Abstract
Massive parallel sequencing enables identification of numerous genetic variants in mutant organisms, but determining pathogenicity of any one mutation can be daunting. The most commonly studied preclinical model of retinitis pigmentosa called the "rodless" (rd1) mouse is homozygous for two mutations: a nonsense point mutation (Y347X) and an intronic insertion of a leukemia virus (Xmv-28). Distinguishing which mutation causes retinal degeneration is still under debate nearly a century after the discovery of this model organism. Here, we performed gene editing using the CRISPR/Cas9 system and demonstrated that the Y347X mutation is the causative variant of disease. Genome editing in the first generation produced animals that were mosaic for the corrected allele but still showed neurofunction preservation despite low repair frequencies. Furthermore, second-generation CRISPR-repaired mice showed an even more robust rescue and amelioration of the disease. This predicts excellent outcomes for gene editing in diseased human tissue, as Pde6b, the mutated gene in rd1 mice, has an orthologous intron-exon relationship comparable with the human PDE6B gene. Not only do these findings resolve the debate surrounding the source of neurodegeneration in the rd1 model, but they also provide the first example of homology-directed recombination-mediated gene correction in the visual system.
Details
- Title: Subtitle
- CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa
- Creators
- Wen-Hsuan Wu - Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, New York, USAYi-Ting Tsai - Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, New York, USASally Justus - Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, New York, USATing-Ting Lee - Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, New York, USALijuan Zhang - Shanxi Eye Hospital, Shanxi Medical University, Taiyuan, Shanxi, ChinaChyuan-Sheng Lin - Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, USAAlexander G Bassuk - Department of Pediatrics and Neurology, University of Iowa, Iowa City, Iowa, USAVinit B Mahajan - Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, USAStephen H Tsang - Edward S. Harkness Eye Institute, New York-Presbyterian Hospital, New York, New York, USA
- Resource Type
- Journal article
- Publication Details
- Molecular therapy, Vol.24(8), pp.1388-1394
- DOI
- 10.1038/mt.2016.107
- PMID
- 27203441
- PMCID
- PMC5023380
- NLM abbreviation
- Mol Ther
- ISSN
- 1525-0016
- eISSN
- 1525-0024
- Publisher
- United States
- Grant note
- R01 EY025225 / NEI NIH HHS R01 EY018213 / NEI NIH HHS R01 EY026682 / NEI NIH HHS R01 EY024698 / NEI NIH HHS
- Language
- English
- Date published
- 08/2016
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics)
- Record Identifier
- 9984020652802771
Metrics
21 Record Views